NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Efficacy and safety of amBisome (liposomal amphotericin B) in primary episodes of cryptococcosis in patients with HIV infection.

Lazar JT, Ksionski GE; International Conference on AIDS.

Int Conf AIDS. 1991 Jun 16-21; 7: 226 (abstract no. W.B.2177).

Vestar, Inc., San Dimas, CA, USA

Cryptococcosis remains a significant cause of morbidity and mortality in patients infected with HIV. Amphotericin B is a mainstay of treatment because of a general lack of pathogen resistance, but its therapeutic efficacy is limited by its toxicity, particularly in patients requiring high doses. AmBisome is a liposomal amphotericin B formulation with greatly reduced toxicity. Nine patients with HIV infection and primary episodes of cryptococcosis were enrolled in a study of AmBisome in cases where amphotericin B was ineffective, toxic or not indicated. Eight patients had cryptococcal meningitis (CCM) and one had both CNS and pulmonary cryptococcosis. CCM was identified by cerebrospinal fluid (CSF) culture in 8 cases and by CSF microscopy and serology in 1. Patients received a maximum of 3.0 mg/kg/day and 50-12,375 mg of AmBisome over 1 - 59 days. One patient died of advanced CCM before a judgment of efficacy could be made. All the remaining 8 patients responded clinically to treatment; 7 (including the case with CCM plus pulmonary cryptococcosis) were clinically cured and 1 was improved. Cryptoccoci were eradicated in 6 of 8 evaluable cases and were cleared from CSF in 7 - 15 days. One patient experienced anemia, thrombocytopenia and hypokalemia that resolved 19 days after the last dose and were not considered unequivocally due to AmBisome. Judgment of the cause of such a reaction is difficult in a patient with poor hematologic function. A second patient experienced rigors hours after dosing on 1 occasion during treatment, and a third patient, experienced occasional transient weakness after dosing. No creatinine or BUN increases, nausea or fever were reported. AmBisome is an effective, well tolerated treatment for primary CCM.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • AmBisome
  • Amphotericin B
  • Cryptococcosis
  • HIV
  • HIV Seropositivity
  • HIV-1
  • Humans
  • Meningitis, Cryptococcal
Other ID:
  • 3217791
UI: 102192781

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov